DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
https://doi.org/10.14412/1995-4484-2012-1177
Abstract
Objective — to evaluate the relationship between antibody titers against modified citrullinated vimentin (AMCV), IgM rheumatoid factor (RF), interleukin (IL) 4, IL6 and IL8, and their correlation with rheumatoid arthritis (RA) activity indicators, systemic manifestations, evolution of disease activity and functional status in patients treated with methotrexate (MT). Material and methods. 76 RA patients were evaluated: 44 — were on MT, 32 — were not receiving DMARDs for <3 months. Serum IgM RF and C-reactive protein (CRP) levels were measured by immunonephelometry, AMCV, IL6, IL8 (ng/Ml) — by solid-phase immunoenzyme analysis. Results. There was no correlation between AMCV levels and RA activity measures (p>0,05). Higher AMCV titers were detected in patients with systemic manifestations vs patients without such symptoms (p=0,002). In subgroup of patients with baseline AMCV >500 U/Ml a significantly lower level of IL6 was observed (p=0,03) with a tendency for AMCV level reduction (p=0,06) and an increase in DAS28 scores after 12 mo of MT therapy (p>0,05). IgM RF titers were significantly higher in patients with high disease activity (p=0,0006) and in patients with systemic manifestations (p=0,04). Significantly higher IL6 levels (p=0,01) and a tendency to DAS28 measures reduction after 12 mo of MT therapy was observed in patients with baseline IgM RF >100 IU/Ml (p>0,05).
References
1. <div><p>Насонов Е.Л., Александрова Е.Н., Новиков А.А. Клиническое значение антител к циклическому цитруллинированному пептиду: новые данные. Клин. мед. 2007; 85(8): 4—9.</p><p>Bang H., Luthke K., Gauliard A. et al. Mutated citrullinated vimentin (MCV) as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Ann Rheum Dis 2006; 65(2): 144.</p><p>Mathsson L., Mullazehi M., Wick M.C. et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthr Rheum 2008; 58; (1): 36—45.</p><p>Ursum J., Nielen M.M., van Schaardenburg D. et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthr Res Ther 2008; 10(1): 12.</p><p>Zimmermann C., Hoefler E., Steiner G. Diagnostic value of anti-CCP and anti-mutated citrullinated vimentin (MCV) testing in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67(2): 149.</p><p>Насонов Е.Л., Андрианова И.А., Фоломеева О.М. и др. Ревматоидный артрит в ревматологической практике России: тяжесть заболевания в российской популяции больных. Одномоментное (поперечное) эпидемиологическое исследование (RAISER). Науч.-практич. ревматол. 2010; 1: 50—61.</p><p>Насонова В.А., Бунчук Н.В. Избранные лекции по клинической ревматологии. М.: Медицина, 2001; 272 с.</p><p>Новиков А.А., Александрова Е.Н., Диатроптова М.А. и др. Роль цитокинов в патогенезе ревматоидного артрита. Науч.-практич. ревматол. 2010; 2: 71—83.</p><p>Bobbio-Pallavicini F., Capoorali R., Alpini C. et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007; 66; (3): 302—7.</p><p>Klaasen R., Cantaert T., Wijbrandts C.A. et al. The relationship between different isotypes (IgM, IgG and IgA) of rheumatoid factor and IgG anticyclic citrullinated peptide antibody and clinical response to infliximab in rheumatoid arthritis. Arthr Rheum 2009; 60(1): 373—4.</p><p>Poter C., Hyrich K.L., Tracey A. et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumor necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009; 68(2): 69—74.</p><p>Visser K., Verpoot K.N., van Dongen H. et al. Pretreatment serum levels of anticyclic citrullinated peptide antibodies are associated with the response to methotrexate on recent — oncet arthritis. Ann Rheum Dis 2008; 67(7): 1194—5.</p><p>Saleem B., Nizam S., Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006; 24(6): 33—6.</p><p>Groot Kormelink T.G., Tekstra J., Thurling R.M. et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis Rituximab (anti-CD20) treatment correlates with decrease activity. Ann Rheum Dis 2010; 10(2): 1136.</p><p>Беляева И.Б., Мазуров В.И. Факторы риска развития эрозивного процесса при раннем ревматоидном артрите (РРА). Матер. V съезда ревматологов России. М., 2009; 65: 21.</p></div><br />
Review
For citations:
Voronina M.S., Vinogradov A.A., Shilkina N.P. DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS. Rheumatology Science and Practice. 2012;50(5):30-33. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1177
Views:
989
Email this article 